Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

The LEAP-001 study evaluated the combination of Keytruda plus Lenvima for the first-line treatment of patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair ...

In the LEAP-002 study, Merck hoped to show that combining Keytruda with Lenvima would improve outcomes over two years' follow-up in patients with unresectable HCC. However, the duo was unable to ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

At the final analysis, Keytruda plus Lenvima did not improve OS or PFS sufficiently to meet the study's prespecified statistical criteria in the first-line treatment of certain patients with ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...

across solid tumors with high microsatellite instability status as well as for Keytruda combined with Eisai and Merck’s ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...